bexmarilimab

DRUG4 trials

Sponsors

Medica Scientia Innovation Research S.L., Faron Pharmaceuticals Ltd, MedSIR

Conditions

Acute Myeloid LeukemiaAdvanced or metastatic histologically confirmed soft tissue sarcoma (STS) in adult patients who are not candidates for curative treatment.Carcinoma ColonCarcinoma, Renal CellChronic Myelomonocytic LeukemiaMyelodysplastic SyndromesRelapsed/Refractory AMLSoft Tissue Sarcoma (STS)

Phase 1

A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma

WithdrawnNCT05104905

Faron Pharmaceuticals LtdCarcinoma Colon, Carcinoma, Renal Cell

Start: 2021-10-07End: 2022-01-28Updated: 2022-05-11

A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies

Active, not recruitingNCT05428969

Faron Pharmaceuticals LtdAcute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes +1

Start: 2022-06-02End: 2027-03-01Target: 181Updated: 2026-04-23

A Phase Ib/II Study to Evaluate Safety and Efficacy of Bexmarilimab in Combination With Doxorubicin in Metastatic Soft-tissue Sarcoma.

RecruitingNCT07460986

MedSIRSoft Tissue Sarcoma (STS)

Start: 2026-08-20End: 2028-10-01Target: 278Updated: 2026-08-31

A PHASE IB/II STUDY TO EVALUATE SAFETY AND EFFICACY OF BEXMARILIMAB IN COMBINATION WITH DOXORUBICIN IN METASTATIC SOFT-TISSUE SARCOMA (BEXAR Study)

Not yet recruitingCTIS2025-525144-18-00

Medica Scientia Innovation Research S.L.Advanced or metastatic histologically confirmed soft tissue sarcoma (STS) in adult patients who are not candidates for curative treatment.

Target: 278Updated: 2026-06-08

Related Papers

Secreted Clever-1 modulates T cell responses and impacts cancer immunotherapy efficacy

Theranostics2025-06-235 citations

Bexmarilimab plus azacitidine for high-risk myelodysplastic syndrome and relapsed or refractory acute myeloid leukaemia: results from the dose-escalation part of a multicentre, single-arm, phase 1/2 trial.

2025-05-283 citations

Efficacy of macrophage checkpoint Clever-1 inhibition with bexmarilimab plus azacitidine in myelodysplastic syndrome: Results from the ph1/2 BEXMAB study.

Journal of Clinical Oncology2025-05-28

CLEVER-1 targeting antibody, bexmarilimab, supports HLA-DR expression and alters ex vivo responsiveness to azacitidine and venetoclax in myeloid malignancies.

2025-05-143 citations

Encouraging Efficacy of Bexmarilimab with Azacitidine in Relapsed or Refractory MDS in Bexmab Ph1/2 Study

Blood2024-11-051 citations

Encouraging Efficacy Observed in Bexmab Study: A Phase 1/2 Study to Assess Safety and Efficacy of Bexmarilimab in Combination with Standard of Care in Myeloid Malignancies

Blood2023-11-022 citations

P542: A PHASE I/II STUDY TO ASSESS SAFETY, TOLERABILITY AND PRELIMINARY EFFICACY OF BEXMARILIMAB IN COMBINATION WITH STANDARD OF CARE IN PATIENTS WITH MYELOID MALIGNANCIES (BEXMAB)

HemaSphere2023-08-01

Abstract A14: Ex vivo immune activation with the macrophage-targeting immunotherapy, anti-Clever-1 antibody bexmarilimab, in acute myeloid leukemia and myelodysplastic syndrome

Blood Cancer Discovery2023-05-011 citations

Trial in Progress: A Phase I/II Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination with Standard of Care in Patients with Hematological Malignancies (BEXMAB)

Blood2022-11-152 citations

709 Phase II Study to assess the safety and efficacy of the CLEVER-1 antibody bexmarilimab in combination with PD-1 blockade in patients with advanced solid tumors – BEXCOMBO

Regular and Young Investigator Award Abstracts2022-11-01